Information

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

  • Register
  • Login
Skip to content
  • Home
  • Issues
    • Allergy & Immunology
    • Cardiology
    • Conference
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes & Endocrinology
    • Gastroenterology
    • General Medicine
    • Haematology
    • Hepatology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Nursing
    • Obstetrics & Gynaecology
    • Oncology
    • Paediatrics
    • Psychiatry
    • Rheumatology
    • Surgery Insights
    • Urology
  • About
  • Contact
  • Register
  • Login

Fig6It

Published May 16, 2016 at 650 × 405 in Dymista®: un nuovo livello di controllo dei sintomi della rinite allergica.
← Previous

Figura 6. Un numero maggiore di pazienti con rinite allergica perenne trattati con Dymista® ha ottenuto il controllo completo dei sintomi raggiungendo tale risultato fino ad otto giorni più rapidamente dei pazienti trattati con FP. Dymista® versus FP: p=0,0063. Ristampata per gentile concessione da J Investig Allergol Clin Immunol24

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Share

Copyright © 2000-2026 by John Wiley & Sons, Inc., or related companies. All rights reserved.
Review our privacy policy. Cookie Preferences.
Web design and marketing agency Leamington Spa